第 1 到 126 筆結果,共 126 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2024 | miR-622 Increases miR-30a Expression through Inhibition of Hypoxia-Inducible Factor 1α to Improve Metastasis and Chemoresistance in Human Invasive Breast Cancer Cells | Cheng, Chun-Wen; Liu, Yu-Fan; Liao, Wen-Ling; Chen, Po-Ming; Hung, Yueh-Tzu; Lee, Huei-Jane; Cheng, Yu-Chun; Wu, Pei-Ei; YEN-SHEN LU ; Shen, Chen-Yang | Cancers | |||
2 | 2024 | A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens | Lee, Yi-Hsuan; Huang, Chung-Yen; Hsieh, Yu-Han; Yang, Chia-Hung; Hung, Yu-Ling; Chen, Yung-An; Lin, Yu-Chieh; Lin, Ching-Hung; JIH-HSIANG LEE ; Wang, Ming-Yang; Kuo, Wen-Hung; Lin, Yen-Yin; YEN-SHEN LU | BMC cancer | |||
3 | 2024 | Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancer | Chou, Wen-Cheng; Chen, Wei-Ting; Kuo, Chun-Tse; Chang, Yao-Ming; YEN-SHEN LU ; Li, Chia-Wei; Hung, Mien-Chie; Shen, Chen-Yang | Cell reports | |||
4 | 2024 | Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial | WEI-WU CHEN ; Dai, Ming-Shen; Tseng, Ling-Ming; Chen, Shin-Cheh; Chao, Tsu-Yi; Chao, Ta-Chung; Chang, Yuan-Ching; Chiu, Chang-Fang; Liu, Chien-Ting; Lin, Ching-Hung; Liu, Chun-Yu; YA-FANG CHEN ; DWANG-YING CHANG ; Yu, Jyh-Cherng; Rau, Kun-Ming; Hsieh, Yao-Yu; Shen, Shih-Che; Huang, Shu-Min; ANN-LII CHENG ; YEN-SHEN LU | JAMA oncology | 0 | ||
5 | 2023 | Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis | Peng, Shang-Hsuan; CHING-HUNG LIN ; I-CHUN CHEN ; YING-CHUN SHEN ; DWANG-YING CHANG ; WEI-WU CHEN ; Huang, Shu-Min; Hu, Fu-Chang; YEN-SHEN LU | Cancer medicine | 0 | 0 | |
6 | 2023 | Lifestyle Factors and Energy Intakes with Risks of Breast Cancer among Pre- and Post- Menopausal Women in Taiwan | Huang, Meng-Chuan; Huang, Tz-Ting; Feng, Hsin-Chun; I-CHUN CHEN ; Chang, Chiao-I; Wang, Tsu-Nai; WEN-HUNG KUO ; Wang, Ming-Yang; LI-WEI TSAI ; Li, Szu-Yi; Huang, Chiun-Sheng; YEN-SHEN LU ; CHING-HUNG LIN | Nutrients | 0 | ||
7 | 2023 | Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials | André, F; Su, F; Solovieff, N; Hortobagyi, G; Chia, S; Neven, P; Bardia, A; Tripathy, D; YEN-SHEN LU ; Lteif, A; Taran, T; Babbar, N; Slamon, D; Arteaga, C L | Annals of oncology : official journal of the European Society for Medical Oncology | 3 | 0 | |
8 | 2023 | The Application of18F-FES PET in Clinical Cancer Care: A Systematic Review | Huang, Ya-Ting; WEI-WU CHEN ; Chen, Li-Yu; Huang, Ya-Yao; YEN-SHEN LU | Clinical nuclear medicine | 0 | 0 | |
9 | 2023 | Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer | WEI-WU CHEN ; Hsiao, Wen; Dai, Ming-Shen; CHING-HUNG LIN ; DWANG-YING CHANG ; I-CHUN CHEN ; MING-YANG WANG ; Chang, Shu-Han; Huang, Shu-Min; ANN-LII CHENG ; Wu, Ko-Wen; Tan, Kien Thiam; YEN-SHEN LU | Breast cancer research and treatment | 0 | 0 | |
10 | 2023 | Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women | CHING-HUNG LIN ; Zahid, Muhammad; WEN-HUNG KUO ; Hu, Fu-Chang; MING-YANG WANG ; I-CHUN CHEN ; Beseler, Cheryl L; Mondal, Bodhisattwa; YEN-SHEN LU ; Rogan, Eleanor G; ANN-LII CHENG | Cancer prevention research (Philadelphia, Pa.) | 0 | 0 | |
11 | 2023 | Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hu, Mickey C-T; CHIUN HSU ; YAO-MING WU ; YEN-SHEN LU ; Ho, Ja-An Annie; Shiou-Hwei Yeh ; PEI-JER CHEN ; ANN-LII CHENG | Cancer letters | 1 | 1 | |
12 | 2023 | Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma | HUANG-CHUN LIEN ; Hsu, Chia-Lang; YEN-SHEN LU ; WEI-WU CHEN ; I-CHUN CHEN ; Li, Yu-Chia; CHIUN-SHENG HUANG ; ANN-LII CHENG ; CHING-HUNG LIN | Breast cancer research : BCR | 0 | 0 | |
13 | 2023 | Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study | Dai, Ming-Shen; Chao, Ta-Chung; Chiu, Chang-Fang; YEN-SHEN LU ; Shiah, Her-Shyong; Jackson, Christopher G C A; Hung, Noelyn; Zhi, Jianguo; Cutler, David L; Kwan, Rudolf; Kramer, Douglas; Chan, Wing-Kai; Qin, Albert; Tseng, Kuan-Chiao; Hung, Cheung Tak; Chao, Tsu-Yi | Therapeutic advances in medical oncology | 0 | 0 | |
14 | 2022 | Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices | WEI-LI MA ; DWANG-YING CHANG ; CHING-HUNG LIN ; KAO-LANG LIU ; PO-CHIN LIANG ; HUANG-CHUN LIEN ; Hu, Chan-Chuan; Huang, Ling-Yun; Yeh, Yi-Chun; YEN-SHEN LU | The oncologist | 0 | 1 | |
15 | 2022 | Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients | PO-HAN LIN ; Chen, Shin-Cheh; Tseng, Ling-Ming; KING-JEN CHANG ; Huang, Ai-Chu; Cheng, Kuo-Chih; Yang, Karen; Wu, Hui-Chen; Chao, Tsu-Yi; Chang, Yuan-Ching; Lin, Peng-Chan; WEN-HUNG KUO ; Kuo, Wen-Lin; CHING-HUNG LIN ; Chen, Huo-Mu; Yeh, Dah-Cherng; Liu, Liang-Chih; Liu, Chun-Yu; MING-YANG WANG ; Chiao Lo ; YEN-SHEN LU ; CHIUN-SHENG HUANG | Breast cancer research and treatment | 5 | 4 | |
16 | 2022 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial | YEN-SHEN LU ; Im S.-A.; Colleoni M.; Franke F.; Bardia A.; Cardoso F.; Harbeck N.; Hurvitz S.; Chow L.; Sohn J.; Lee K.S.; Campos-Gomez S.; Vazquez R.V.; Jung K.H.; Babu K.G.; Wheatley-Price P.; De Laurentiis M.; Im Y.-H.; Kuemmel S.; El-Saghir N.; O'Regan R.; Gasch C.; Solovieff N.; Wang C.; Wang Y.; Chakravartty A.; Ji Y.; Tripathy D. | Clinical Cancer Research | 75 | 38 | |
17 | 2022 | HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis | Tan R.S.Y.C.; Ong W.S.; Lee K.-H.; Lim A.H.; Park S.; Park Y.H.; CHING-HUNG LIN ; YEN-SHEN LU ; Ono M.; Ueno T.; Naito Y.; Onishi T.; Lim G.-H.; Tan S.-M.; Lee H.-B.; Ryu H.S.; Han W.; Tan V.K.M.; Wong F.-Y.; Im S.-A.; Tan P.H.; Chan J.Y.; Yap Y.-S. | BMC Medicine | 53 | 41 | |
18 | 2022 | A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer | Kuemmel S.; Campone M.; Loirat D.; Lopez R.L.; Thaddeus Beck J.; de Laurentiis M.; Im S.-A.; Kim S.-B.; Kwong A.; Steger G.G.; Adelantado E.Z.; Duhoux F.P.; Greil R.; Kuter I.; YEN-SHEN LU ; Tibau A.; ?zg?ro?lu M.; Scholz C.W.; Singer C.F.; Vega E.; Wimberger P.; Zamagni C.; Couillebault X.-M.; Fan L.; Guerreiro N.; Mataraza J.; Sand-Dejmek J.; Chan A. | Clinical Cancer Research | 15 | 15 | |
19 | 2021 | Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients | I-CHUN CHEN ; Hu, Fu-Chang; CHING-HUNG LIN ; Huang, Shu-Min; DWANG-YING CHANG ; ANN-LII CHENG ; YEN-SHEN LU | Breast (Edinburgh, Scotland) | 2 | 2 | |
20 | 2021 | High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia | LIN, CHING-HUNG ; RUBY YUN-JU HUANG ; TZU-PIN LU ; KUAN-TING KUO ; Lo, Ko-Yun; Chen, Ching-Hsuan; I-CHUN CHEN ; YEN-SHEN LU ; ERIC YAO-YU CHUANG ; Thiery, Jean Paul; CHIUN-SHENG HUANG ; ANN-LII CHENG | NPJ breast cancer | 4 | 4 | |
21 | 2021 | A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer | Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU ; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. | Breast Cancer Research | 17 | 15 | |
22 | 2021 | Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer | Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU ; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. | Clinical Cancer Research | 14 | 10 | |
23 | 2021 | Role of alpelisib in the treatment of pik3ca-mutated breast cancer: Patient selection and clinical perspectives | DWANG-YING CHANG ; WEI-LI MA ; YEN-SHEN LU | Therapeutics and Clinical Risk Management | 28 | 24 | |
24 | 2021 | Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib | Bardia A.; Su F.; Solovieff N.; Im S.-A.; Sohn J.; Lee K.S.; Campos-Gomez S.; Jung K.H.; Colleoni M.; V?zquez R.V.; Franke F.; Hurvitz S.; Harbeck N.; Chow L.; Taran T.; Lorenc K.R.; Babbar N.; Tripathy D.; YEN-SHEN LU | JCO Precision Oncology | |||
25 | 2021 | Matching-adjusted indirect comparison of ribociclib plus fulvestrant versus palbociclib plus letrozole as first-line treatment of hr+/her2? advanced breast cancer | Fasching P.A.; Delea T.E.; YEN-SHEN LU ; De Boer R.; Hurvitz S.A.; Moynahan A.; Chandiwana D.; Lanoue B.; Hu H.; Thuerigen A.; O��shaughnessy J. | Cancer Management and Research | 1 | 0 | |
26 | 2021 | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens | Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU ; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. | Breast Cancer Research and Treatment | 10 | 10 | |
27 | 2021 | Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components | HUANG-CHUN LIEN ; Lee Y.-H.; I-CHUN CHEN ; CHING-HUNG LIN ; WEI-WU CHEN ; Lu Y.-T.; YEN-SHEN LU | Virchows Archiv | 15 | 13 | |
28 | 2021 | Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs | Hata T.; Nakamura K.; Yonemori K.; Noguchi E.; Watanabe M.; Sohn J.; YEN-SHEN LU ; Yap Y.-S.; Tamura K.; Fujiwara Y. | Clinical and Translational Science | 2 | 1 | |
29 | 2021 | A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer | YEN-SHEN LU ; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. | Clinical Cancer Research | 23 | 16 | |
30 | 2021 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1 | André F.; Ciruelos E.M.; Juric D.; Loibl S.; Campone M.; Mayer I.A.; Rubovszky G.; Yamashita T.; Kaufman B.; YEN-SHEN LU ; Inoue K.; Pápai Z.; Takahashi M.; Ghaznawi F.; Mills D.; Kaper M.; Miller M.; Conte P.F.; Iwata H.; Rugo H.S. | Annals of Oncology | 279 | ||
31 | 2020 | Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) | Harbeck N.; Franke F.; Villanueva-Vazquez R.; YEN-SHEN LU ; Tripathy D.; Chow L.; Babu G.K.; Im Y.-H.; Chandiwana D.; Gaur A.; Lanoue B.; Rodriguez-Lorenc K.; Bardia A. | Therapeutic Advances in Medical Oncology | 36 | 31 | |
32 | 2020 | Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial | Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU ; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators | Journal of Clinical Oncology | 360 | 311 | |
33 | 2020 | Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations | Chen C.-H.; YEN-SHEN LU ; ANN-LII CHENG ; CHIUN-SHENG HUANG ; WEN-HUNG KUO ; Wang M.-Y.; Chao M.; I-CHUN CHEN ; Kuo C.-W.; TZU-PIN LU ; CHING-HUNG LIN | Oncologist | 32 | 32 | |
34 | 2020 | Mortality of Pregnancy Following Breast Cancer Diagnoses in Taiwanese Women | Chuang S.-C.; CHING-HUNG LIN ; YEN-SHEN LU ; Hsiung C.A. | Oncologist | 3 | 4 | |
35 | 2020 | Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival | WEI-WU CHEN ; I-SHIOW JAN ; DWANG-YING CHANG ; CHING-HUNG LIN ; I-CHUN CHEN ; Chen H.-M.; ANN-LII CHENG ; YEN-SHEN LU | Journal of Neuro-Oncology | 17 | 13 | |
36 | 2020 | A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women | Lien, Guang-Wen; WU-SHIUN HSIEH ; WEN-HUNG KUO ; CHING-HUA KUO ; Huang, Ching-Chun; YUE-LIANG GUO; DWANG-YING CHANG ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; ANN-LII CHENG ; CHING-HUNG LIN ; PAU-CHUNG CHEN | Environment International | 48 | 35 | |
37 | 2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS | Park Y.H; Senkus-Konefka E; Im S.-A; Pentheroudakis G; Saji S; Gupta S; Iwata H; Mastura M.Y; Dent R; YEN-SHEN LU ; Yin Y; Smruti B.K; Toyama T; Malwinder S; Lee S.C; Tseng L.-M; Kim J.H; Kim T.-Y; Suh K.J; Cardoso F; Yoshino T; Douillard J.-Y. | Annals of Oncology | 34 | 29 | |
38 | 2019 | Overall survival with ribociclib plus endocrine therapy in breast cancer | Im S.-A; YEN-SHEN LU ; Bardia A; Harbeck N; Colleoni M; Franke F; Chow L; Sohn J; Lee K.-S; Campos-Gomez S; Villanueva-Vazquez R; Jung K.-H; Chakravartty A; Hughes G; Gounaris I; Rodriguez-Lorenc K; Taran T; Hurvitz S; Tripathy D. | New England Journal of Medicine | 607 | 556 | |
39 | 2019 | Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models | Kuo C.-T.; Chen C.-L.; Li C.-C.; Huang G.-S.; Ma W.-Y.; Hsu W.-F.; CHING-HUNG LIN ; YEN-SHEN LU ; ANDREW WO | Scientific Reports | 6 | 5 | |
40 | 2019 | Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer | Andr? F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo H.S; Iwata H; Conte P; Mayer I.A; Kaufman B; Yamashita T; YEN-SHEN LU ; Inoue K; Takahashi M; P?pai Z; Longin A.-S; Mills D; Wilke C; Hirawat S; Juric D. | New England Journal of Medicine | 1440 | 1286 | |
41 | 2019 | PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study | MING-HAN YANG ; I-CHUN CHEN ; YEN-SHEN LU | Journal of the Formosan Medical Association | 21 | 17 | |
42 | 2019 | Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population | CHING-HUNG LIN ; Yap Y.S.; Lee K.-H.; Im S.-A.; Naito Y.; Yeo W.; Ueno T.; Kwong A.; Li H.; Huang S.-M.; Leung R.; Han W.; Tan B.; Hu F.-C.; CHIUN-SHENG HUANG ; ANN-LII CHENG ; YEN-SHEN LU ; Asian Breast Cancer Cooperative Group | Journal of the National Cancer Institute | 81 | 73 | |
43 | 2019 | Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer | Iwata H; Masuda N; Kim S.-B; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; YEN-SHEN LU ; Xu B; Yap Y.S; Bustam A; Yao B; Zhang B; Bryce R; Chan A. | Future Oncology | 9 | 7 | |
44 | 2018 | Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS | Chiu, Huai Hsuan; Liao, Hsiao Wei; YU-YUN SHAO ; YEN-SHEN LU ; CHING-HUNG LIN ; Tsai, I. Lin; CHING-HUA KUO | Analytica Chimica Acta | 49 | 45 | |
45 | 2018 | A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer | WEI-WU CHEN ; Yeh D.-C.; Chao T.-Y.; CHING-HUNG LIN ; Chow L.W.-C.; DWANG-YING CHANG ; Hsieh Y.-Y.; Huang S.-M.; ANN-LII CHENG ; YEN-SHEN LU ; Taiwan Breast Cancer Consortium | Japanese Journal of Clinical Oncology | 4 | 3 | |
46 | 2018 | Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial | Tripathy D; Im S.-A; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz S.A; Chow L; Sohn J; Lee K.S; Campos-Gomez S; Villanueva Vazquez R; Jung K.H; Babu K.G; Wheatley-Price P; De Laurentiis M; Im Y.-H; Kuemmel S; El-Saghir N; Liu M.-C; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; YEN-SHEN LU | The Lancet Oncology | 633 | 545 | |
47 | 2018 | Adiposity, inflammation, and breast cancer pathogenesis in Asian Women | Iyengar N.M.; I-CHUN CHEN ; Zhou X.K.; Giri D.D.; Falcone D.J.; Winston L.A.; Wang H.; Williams S.; YEN-SHEN LU ; Hsueh T.-H.; ANN-LII CHENG ; Hudis C.A.; CHING-HUNG LIN ; Dannenberg A.J. | Cancer Prevention Research | 32 | 30 | |
48 | 2018 | Effect of glucocorticoid use on survival in patients with stage I–III breast cancer | CHING-HUNG LIN ; Chuang P.-Y.; You S.-L.; CHUN-JU CHIANG ; CHIUN-SHENG HUANG ; Wang M.-Y.; Chao M.; YEN-SHEN LU ; ANN-LII CHENG ; Tang C.-H. | Breast Cancer Research and Treatment | 8 | 8 | |
49 | 2018 | Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer | BANG-BIN CHEN ; YEN-SHEN LU ; CHIH-WEI YU ; CHING-HUNG LIN ; WEI-WU CHEN ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | European Radiology | 9 | 9 | |
50 | 2018 | Association of pregnancy and mortality in women diagnosed with breast cancer: A Nationwide Population Based Study in Taiwan | Chuang S.-C.; CHING-HUNG LIN ; YEN-SHEN LU ; Hsiung C.A. | International Journal of Cancer | 10 | 9 | |
51 | 2017 | Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients | Chow L.W.C.; Biganzoli L.; Leo A.D.; Kuroi K.; Han H.S.; Patel J.; CHIUN-SHENG HUANG ; YEN-SHEN LU ; Zhu L.; Chow C.Y.C.; Loo W.T.Y.; Gl?ck S.; Toi M. | Asia-Pacific Journal of Clinical Oncology | 16 | 17 | |
52 | 2017 | Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen | I-CHUN CHEN ; Hsiao L.-P.; Huang I.-W.; Yu H.-C.; Yeh L.-C.; CHING-HUNG LIN ; Wei-Wu Chen T.; ANN-LII CHENG ; YEN-SHEN LU | Scientific Reports | 23 | 20 | |
53 | 2017 | Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma | Chiu H.-H.; Tsai I.-L.; YEN-SHEN LU ; CHING-HUNG LIN ; CHING-HUA KUO | Analytical and Bioanalytical Chemistry | 20 | 15 | |
54 | 2017 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial | Martin, Miguel; Holmes, Frankie A; Ejlertsen, Bent; Delaloge, Suzette; Moy, Beverly; Iwata, Hiroji; von Minckwitz, Gunter; Chia, Stephen K L; Mansi, Janine; Barrios, Carlos H; Gnant, Michael; KING-JEN CHANG ; Arance A.M; Efrat N; Sarosiek T; Grzeda L; Manalo Y; Smith J.C; Vaziri I; Healey T; Rahim Y; Toma?evi? Z; Luk C; Dingle B; Franco S; Sorensen P.G; Anand A; Khan S; Fountzilas G; Aogi K; Shimizu S; Mikulova M; Denduluri N; Spanik S; Somer R.A; Flynn P.J; Coward J; Mainwaring P; Jerusalem G; Segura-Ojezzar C; Levy C; Delozier T; Khayat D; ?eparovi? R; Coleman R.E; Rolles M.J; Maisano R; Nardi M; Ito Y; Yumuk P.F; Basaran G; Serdar Turhal N; Wilkinson M.J; Green N.B; Gokmen E; Sidrys A.P; Hallmeyer S; Testori D.J; Sridhar S; Chang J; Sun Q; Jara-Sanchez C; Rubio X; Garrido M.L; De La Haba Rodriguez J.R; Bashford A; Perello Martorell A; Avelia Mestre A; Rifa Ferrer J; del Barco Berron S; Nagy Z; Tanaka M; Im Y.-H; Carroll R.R; Dickerson L.C; Mace J.R; Ruiz Borrego M; Rivera R; Klein L.M; Ruxer R; Wilks S.T; Kotasek D; Popov V; Taskova V; Marinova-Venkova V; Timcheva C; Desbiens C; Kim S.-B; Ayoub J.-P; Grenier D; Marschner N; Tesch H; Lueck H.-J; Janssen J; Schwaner I; Wahlstrom S; Brix E.H; Vallentin S; Jakobsen E.H; Kristensen D; Andreeva A; Glavicic V; Calvo Plaza I; Anton Torres A; Veyret C; Bergerat J.-P; Bourbouloux E; Ella W.A; Algurafi H; Ciceniene A; Robinson A; Kim S.J; Taguchi T; Juozaityte E; Madretsma S; Radema S; Czerniawska-Meier M; Rogowski W; Wagnerova M; Richards D.A; Inoue K; Tan-Chiu E; Vasileios A; Henderson C.A; Holden V.R; Wang X; Tong Z; Yang J; Gonzalez M.E; Rezai M; Hackmann J; Overkamp F; de Due?as E.M; de las Heras B.B; Dourthe L.M; Chocteau-Bouju D; Bougnoux P; Kakolyris S; Kalofonos H; Pectasidis D; Ng T.Y; Pajkos G; Heijns J.B; Somogyine E.E; Tonini G; Giuffrida D; Takao S; Ishitobi M; Inaji H; Tokuda Y; Wozniak K; Lungulescu D; YEN-SHEN LU ; Armstrong A.C; Chang K.-J; Hill J; Croot C.C; Dekker A; Belman N.D; Conde M; Michaelson R.A; Kemmer K; Chui S; Luoh S.-W; Link J.S; Nahum K; Greenspan A.R; Nichols J.C; Encarnacion C.A; Niederman T.M.J; Lee T; Alexander R; Gordon R; Tomova A; Rauch D; Joy A.A; Popescu R.A; Rojas G.A; Vanasek J; Neunhoeffer T; Barinoff J; Graffunder G; Wolfgang A; Bojko P; Heinrich B; von der Assen A; Bryce R; Antonovic B.J; Adrian L; Ramos Vazquez M; Gonzalez Santiago S; Dieras V; Bishop J.M; Perren T.J; Varthalitis I; Mavroudis D; Georgoulias V; Wong A; Chow L.W.C; Yau C.C.T; Liang R.H.-S; Pik? B; W?ber A; Kaufman B; Drumea K; Nuzzo F; De Matteis A; Nuzzo F; Moran S; Carteni G; Tokunaga E; Ishida M; Ohno S; Sato N; Kuroi K; Nishimura R; Watanabe J; Choi Y.J; Park K.H; Yao B; Wojtukiewicz M; Jassem J; Loman N; Askoy S; Altundag M.K; Saip P; Ali M.A; Wade J.L; III, Chien A.J; Brandt D; Xu F; Novik Y; Jani C; Rice R.L; Gaffar Y.A.R; Keaton M.R; Bajaj R; Kimmick G; Campbell D; De Boer R.H; Turnquest T; Auerbach A; Lucas S; Dube P; Xu B; Schilling J; Apel K; Sorensen P.G; Vestlev P.M; Jensen B.B; Haahr V; Lescure A.R; Buyse M; Grana Suarez B; Saura Manich C; Jacquin J.-P; Samreen A; Boiangiu I; Dank M; Falci C; Jirillo A; Cinieri S; Ueno T; Chan A; Sato F; Yamashiro H; Sugie T; Lee K.S; Ro J.S; Park I.H; Bustam A.Z; Suszko-Kazarnowicz M; Piktel A; Krzemieniecki K; Harvey V; Iorga P.G; Yap Y.S; Kakalejcik M; Sevinc A; Ozguroglu M; Chen S.-C; Greenberg R.H; Eisemann A.D; Droder R; Abbasi M.R; Tomek R; Vaysburd M; Caldera H.J; Haley B.B; Robin E; Inhorn R.C; Hufnagel D; Kenyon P.D; Spremulli E; Silverman P; Jain S; Robert N.J; Weigand R; Mebis J; Koynova T; Lesperance B; Prausova J; Kohne C.-H; Schneeweiss A; Jackisch C; Fuxius S; Cubedo Cervera R; Gore I; Urruticoechea Ribate A; Pernas Simon S; Valero Gallego J; Arcusa Lanza A; del Pilar Alvarez M; Florian Gerico J; Cany L; Stebbing J; Labudovic D; Gugic D; Jr; Vrbanec D; Roila F; Barni S; Bidoli P; Mukai H; Bermudez V; Eniu A; Mirtsching B.C; Ibrahim E; Trey J; Smith J.W; Hergenroeder P.F; Mahmood A; Gonzalez A; Kaplan E.H; Ban S; Patel D; Clowney B; Hoelzer K; Schwartz G.H; Salkeni M; II, Masuda N; Abraham J; Narula S; Jabboury K; Mocharnuk R.S; McDonough R.H; Sikes D.H; Kawanchi R.H; Schlabach L; McCachren S.S; Jr; Di Sean Kendall S; Cosgriff T.M; Dreisbach L; DeMichele A; Pawl L; Lucas J; Shinn L.C; Alkhouri N; Monga M; Lindquist D.L; Anderson T.C; Harker W.G; Khurshid H; Witherby S; Erickson N; Traynor A; Bose R; Pluard T.J; Jones M.C; Prakash S; Volterra F; Capo G; Petrakova K; Flaherty L.E; Gartner E; Baidas S; Okazaki I; Nguyen B; Rakowski T; Oliff I; Leach J.W; Anderson D; Kubiak K; Guerrero Zotano A; Tsai M; Vroman P; Deleu I; Lybaert W; Borms M; Couture F; Wilson J.J; Hunt G; Holland D.R; Mingrone W; Simon A.R; Wang S; Liu D; Jiang Z; Benesova V; Smakal M; Garnolova P; Vesper A.-S; Neumann M; Janni W; Liedtke C; Konstantinovic Z.N; Fischer D; Grischke E.-M; Seeger D; Moebus V; Prechtl A; Carlos Camara Toral J; Sanchez Munoz A; Gonzalez Jimenez S; Cassinello Espinosa J; Cirauqui B; Iannotti N.O; Margeli Vila M; Batista Lopez N; Chacon Lopez-Muniz J.I; de la Cruz Mora M.A; Mailliez A; Vanlemmens L; Pouessel D; Espie M; Conibear J; Roylance R; Tassone P; Harnett A; Geffen D; Ruggeri E.M; Gamucci T; Van Groeningen C.J; Banas R; Alkis N; Hou M.-F; Krie A.K; Vrindavanam N.S; Rodriguez G.I; Howard O.M; Citrin D; Morginstin M.S; Desai A; Sanchez I.J; Nixon D.A; Jr; Beatty P.G; Edmiston K; McLaughlin M; J??ez Martinez N; Eneman J.D; Lynch C.A; O'Brien E; Call J.A; Lanier K.S; Conlin A; Brooks D.J; McIntyre K; Saltzman M.A; Castine M.J; Crespo Massieu C; III, Ortega G.L; Choi Y.M; Reynolds C.H; Brescia F.A; Kramer R; Kohn A.D; Micha J.P; Rhee J.M; Shah S; Riseberg D.A; Smickoska S; Patterson W.K; Salmon J.-P; Andre C; Bols A; D'hondt R; Luce S; Nouwynck C; Pelgrims G; Richard V; Verschuere J; Somali I; Geldhof K; Caspar C; Luo R; Bednarik O; Schwedler K; Schmidt M; Neumeister R; Bischoff J; Rack B; Repp R; Yilmaz U; Fries S; Adrion R; Schulz V; Klare P; Danei M; Ossenbuhl D; Kusche J.M; Griesinger F; Baena Canada J.M; Martinez del Prado P; Alonso M.G; Machover D; Mayeur D; Trufflandier N; Delecroix V; Mousseau M; Mouret-Reynier M.-A; Nabholtz J.-M; Chetiyawardana A.D; Papandreou C; Hornyak L; Rosales A.M; Faluhelyi Z; Simo E; Di Palma M; Cognetti F; Gorzegno G; Dogliotti L; Gridelli C; Falcone A; Soto Parra H; Buscarino C; Cold S; Im S.-A; Sanchez Llamas B; Dercksen W; Erdkamp F; Ruit J.B; Braun H; Portielje J.E.A; Ciltas A; Buyukberber S; Benekli M; Knoop A.S; Zahalsky A.J; Jaslow R; Thomas G.W; Maini A; Wiznitzer I; Khojasteh A; Francisco Gonzalez M; Kong L.R; Padmanabhan A; Conkright W.A; Patt D; Swain S.M; Faig D.E; Jain K; Yanagihara R.H; Ottaviano Y; Delmas A; Steele H.A; Rainey G.K; Harris P.J; Burris J.K; Hellerstedt B.A; Rupard E.J; Tan E; Whitworth P.W; Bova A.R; Anderson I.C; Shirinian M; Tin-u C; O'Rourke T.J; Roberts M.S; Francisco M; Morales Murillo S; Pierson A.S; Byeff P.D; Kovach P.A; Caton J.R; Rarick M.U; Schimidt W.G; Stopeck A.T; Swart R; Mayer I.A; Carrillo Flores M.R; Alemany C.A; Lozada B; Weinstein P.L; Wang W; Porubcin M; Ellison D.M; Geils G.F; Rivera E; Charif M; Means-Powell J.A; ExteNET Study Group; Hui R; Senecal F.M; De Boer R.H; Shen Z; Luczak A.A; Chui J.W.Y; Tsang J.W.-H; Lang I; Rai Y; Hozumi Y; Ten Tije A.J; Bhandari M; Osborne C.R.C; Ohtani S; Higaki K; Watanabe K; Taguchi K; Takahashi M; Filipovic S; Hansen V.L; Rao V.P; Gupta M; Petrov P; Coudert B; Vojnovic Z; Polya Z; Miyaki T; Yamamoto N; Brincat S; Lesniewski-Kmak K; Chmielowska E; Birhiray R.E; Citron M.L; Papish S.W; Berry W.R; Langkjer S.T | The Lancet Oncology | 445 | 387 | |
55 | 2016 | Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer | PO-HAN LIN ; WEN-HUNG KUO ; Huang A.-C.; YEN-SHEN LU ; CHING-HUNG LIN ; SUNG-HSIN KUO ; Wang M.-Y.; Liu C.-Y.; Cheng F.T.-F.; Yeh M.-H.; Li H.-Y.; Yang Y.-H.; Hsu Y.-H.; Fan S.-C.; Li L.-Y.; SUNG-LIANG YU ; KING-JEN CHANG ; PEI-LUNG CHEN ; YEN-HSUAN NI ; CHIUN-SHENG HUANG | Oncotarget | 74 | 64 | |
56 | 2016 | Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer | I-CHUN CHEN ; Chang Y.-C.; YEN-SHEN LU ; KUEI-PIN CHUNG ; CHIUN-SHENG HUANG ; TZU-PIN LU ; WEN-HUNG KUO ; Wang M.-Y.; KUAN-TING KUO ; Wu P.-F.; Hsueh T.-H.; Shen C.-Y.; CHING-HUNG LIN ; ANN-LII CHENG | Scientific Reports | 18 | 17 | |
57 | 2016 | Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer | Love R.R.; Hossain S.M.; Hussain Md.M.; Mostafa M.G.; Laudico A.V.; Siguan S.S.S.; Adebamowo C.; Sun J.-Z.; Fei F.; Shao Z.-M.; Liu Y.; Akram Hussain S.Md.; Zhang B.; Cheng L.; Panigaro S.; Walta F.; Chuan J.H.; Mirasol-Lumague M.R.; Yip C.-H.; Navarro N.S.; Jr.; CHIUN-SHENG HUANG ; YEN-SHEN LU ; Ferdousy T.; Salim R.; Akhter C.; Nahar S.; Uy G.; Young G.S.; Hade E.M.; Jarjoura D. | European Journal of Cancer | 6 | 5 | |
58 | 2016 | A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer | BANG-BIN CHEN ; YEN-SHEN LU ; CHING-HUNG LIN ; WEI-WU CHEN ; Wu P.-F.; CHAO-YU HSU ; CHIH-WEI YU ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | BMC Cancer | 20 | 17 | |
59 | 2016 | Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1–2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy | SHIH-FAN LAI ; YU-HSUAN CHEN ; WEN-HUNG KUO ; HUANG-CHUN LIEN ; Wang M.-Y.; YEN-SHEN LU ; Chiao Lo ; SUNG-HSIN KUO ; ANN-LII CHENG ; CHIUN-SHENG HUANG | Annals of Surgical Oncology | 31 | 28 | |
60 | 2016 | Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis | I-CHUN CHEN ; CHING-HUNG LIN ; I-SHIOW JAN ; ANN-LII CHENG ; YEN-SHEN LU | Journal of the Formosan Medical Association | 18 | 11 | |
61 | 2015 | Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient | Wu L.-A.; Chang R.-F.; CHIUN-SHENG HUANG ; YEN-SHEN LU ; Chen H.-H.; JO-YU CHEN ; YEUN-CHUNG CHANG | Journal of Magnetic Resonance Imaging | 17 | 19 | |
62 | 2015 | Associations between medical conditions and breast cancer risk in asians: A nationwide population-based study in Taiwan | Chuang S.-C.; Wu G.-J.; YEN-SHEN LU ; CHING-HUNG LIN ; Hsiung C.A. | PLoS ONE | 28 | 27 | |
63 | 2015 | High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country | CHING-HUNG LIN ; Shen C.-Y.; JIH-HSIANG LEE ; CHIUN-SHENG HUANG ; CHIH-HSIN YANG ; WEN-HUNG KUO ; DWANG-YING CHANG ; Hsiung C.-N.; KUAN-TING KUO ; WEI-WU CHEN ; I-CHUN CHEN ; Wu P.-F.; SUNG-HSIN KUO ; Chen C.-J.; YEN-SHEN LU ; ANN-LII CHENG | PLoS ONE | 10 | 6 | |
64 | 2015 | Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy | YEN-SHEN LU ; WEI-WU CHEN ; CHING-HUNG LIN ; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; BANG-BIN CHEN ; Chao T.-C.; Huang S.-M.; CHIUN-SHENG HUANG ; TIFFANY TING-FANG SHIH ; ANN-LII CHENG ; Taiwan Breast Cancer Consortium | Clinical Cancer Research | 65 | 59 | |
65 | 2015 | A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis | Wu P.-F.; CHING-HUNG LIN ; CHING-HUA KUO ; WEI-WU CHEN ; Yeh D.-C.; Liao H.-W.; Huang S.-M.; ANN-LII CHENG ; YEN-SHEN LU | BMC Cancer | 48 | 36 | |
66 | 2015 | TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays | CHING-HUNG LIN ; Chen I.-C.; CHIUN-SHENG HUANG ; Hu F.-C.; WEN-HUNG KUO ; KUAN-TING KUO ; Wang C.-C.; Wu P.-F.; DWANG-YING CHANG ; Wang M.-Y.; Chang C.-H.; WEI-WU CHEN ; YEN-SHEN LU ; ANN-LII CHENG | Scientific Reports | 10 | 11 | |
67 | 2014 | Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an east Asian country: A nationwide cancer registry-based study | CHING-HUNG LIN ; Chuang P.-Y.; CHUN-JU CHIANG ; YEN-SHEN LU ; ANN-LII CHENG ; WEN-HUNG KUO ; CHIUN-SHENG HUANG ; Lai M.-S.; You S.-L.; Tang C.-H. | Oncologist | 39 | 39 | |
68 | 2014 | No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen | WEI-WU CHEN ; Chen H.-M.; CHING-HUNG LIN ; CHIUN-SHENG HUANG ; ANN-LII CHENG ; Lai M.-S.; YEN-SHEN LU | Breast Cancer Research and Treatment | 10 | 8 | |
69 | 2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 62 | 64 | |
70 | 2014 | Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance | HUANG-CHUN LIEN ; Lee Y.-H.; YUNG-MING JENG ; CHING-HUNG LIN ; YEN-SHEN LU ; Yao Y.-T. | Histopathology | 33 | 28 | |
71 | 2014 | Quantification of target analytes in various biofluids using a postcolumn infused-internal standard method combined with matrix normalization factors in liquid chromatography-electrospray ionization mass spectrometry | Liao H.-W.; Tsai I.-L.; GUAN-YUAN CHEN ; YEN-SHEN LU ; CHING-HUNG LIN ; CHING-HUA KUO | Journal of Chromatography A | 12 | 12 | |
72 | 2013 | Distant metastasis in triple-negative breast cancer | Tseng L.M.; Hsu N.C.; Chen S.C.; YEN-SHEN LU ; CHING-HUNG LIN ; DWANG-YING CHANG ; Li H.; Lin Y.C.; Chang H.K.; Chao T.C.; Ouyang F.; Hou M.F. | Neoplasma | 94 | 85 | |
73 | 2013 | Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation | CHING-HUNG LIN ; Liu J.M.; YEN-SHEN LU ; Lan C.; Lee W.-C.; KUAN-TING KUO ; Wang C.-C.; DWANG-YING CHANG ; CHIUN-SHENG HUANG ; ANN-LII CHENG | Journal of Clinical Pathology | 13 | 14 | |
74 | 2013 | Differential expression of ubiquitin carboxy-terminal hydrolase L1 in breast carcinoma and its biological significance | HUANG-CHUN LIEN ; Wang C.-C.; CHING-HUNG LIN ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; Hsiao L.-P.; Yao Y.-T. | Human Pathology | 12 | 12 | |
75 | 2013 | Benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in the treatment of stage IV breast cancer patients | Dewi S; Larsen S; Srimuninnimit V; YEN-SHEN LU ; Manuaba T; Lindk?r-Jensen S. | Open Breast Cancer Journal | 7 | 0 | |
76 | 2013 | The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines | WEI-WU CHEN ; DWANG-YING CHANG ; Huang S.-M.; CHING-HUNG LIN ; CHIUN HSU ; Lin M.-H.; CHIUN-SHENG HUANG ; YEN-SHEN LU ; ANN-LII CHENG | Breast | 4 | 5 | |
77 | 2013 | Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas | Wu P.-F.; Huang W.-C.; CHIH-HSIN YANG ; YEN-SHEN LU ; JIN-YUAN SHIH ; SHANG-GIN WU ; CHING-HUNG LIN ; ANN-LII CHENG | Journal of Neuro-Oncology | 8 | 5 | |
78 | 2013 | CYP19 genetic polymorphism haplotype aasa is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer | SUNG-HSIN KUO ; Yang, Shi-Yi; HUANG-CHUN LIEN ; Chiao Lo ; CHING-HUNG LIN ; YEN-SHEN LU ; ANN-LII CHENG ; KING-JEN CHANG ; CHIUN-SHENG HUANG | BioMed Research International | 9 | 9 | |
79 | 2012 | The emerging epidemic of estrogen-related cancers in young women in a developing Asian country | CHING-HUNG LIN ; Chen Y.-C.; CHUN-JU CHIANG ; YEN-SHEN LU ; KUAN-TING KUO ; CHIUN-SHENG HUANG ; WEN-FANG CHENG ; Lai M.-S.; You S.-L.; ANN-LII CHENG | International Journal of Cancer | 46 | 45 | |
80 | 2012 | Hashimoto's encephalopathy as the cause of deteriorating consciousness during treatment of leptomeningeal carcinomatosis from breast cancer | YI-HSIN LIANG ; Wu P.-F.; CHING-HUNG LIN ; YEN-SHEN LU | Journal of Clinical Oncology | 0 | 0 | |
81 | 2012 | Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition | Wang C.-C.; JAU-YU LIAU ; YEN-SHEN LU ; Chen J.-W.; Yao Y.-T.; HUANG-CHUN LIEN | Histopathology | 40 | 36 | |
82 | 2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
83 | 2012 | The impact of diabetes mellitus on prognosis of early breast cancer in Asia | WEI-WU CHEN ; YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; YEN-SHEN LU ; Chen H.-M.; Kuo R.N.C.; ANN-LII CHENG ; Lai M.-S. | Oncologist | 36 | 34 | |
84 | 2012 | Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy | Kuo Y.-H.; CHING-HUNG LIN ; Shau W.-Y.; Chen T.-J.; SHIH-HUNG YANG ; Huang S.-M.; CHIUN HSU ; YEN-SHEN LU ; ANN-LII CHENG | BMC Cancer | 19 | 16 | |
85 | 2012 | Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma | YEN-SHEN LU ; Chou C.-H.; KAI-YUAN TZEN ; Gao M.; ANN-LII CHENG ; Kulp S.K.; CHIA-HSIEN CHENG | International Journal of Radiation Oncology Biology Physics | 21 | 20 | |
86 | 2012 | Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer | WEN-HUNG KUO ; PO-HAN LIN ; Huang A.-C.; YIN-HSIU CHIEN ; Liu T.-P.; YEN-SHEN LU ; Bai L.-Y.; Sargeant A.M.; CHING-HUNG LIN ; ANN-LII CHENG ; FON-JOU HSIEH ; WUH-LIANG HWU ; KING-JEN CHANG | Journal of Human Genetics | 19 | 19 | |
87 | 2011 | The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer | JANE WANG ; TIFFANY TING-FANG SHIH ; RUOH-FANG YEN ; YEN-SHEN LU ; Chen C.-Y.; TSUI-LIEN MAO ; CHING-HUNG LIN ; WEN-HUNG KUO ; Tsai Y.-S.; KING-JEN CHANG ; KUO-LIONG CHIEN | Academic Radiology | 10 | 7 | |
88 | 2011 | IκB kinases increase Myc protein stability and enhance progression of breast cancer cells | Yeh P.-Y.; YEN-SHEN LU ; DA-LIANG OU ; ANN-LII CHENG | Molecular Cancer | 24 | 23 | |
89 | 2011 | Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001 | SUNG-HSIN KUO ; CHIH-HUNG HSU ; Chen L.-T.; YEN-SHEN LU ; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH ; ANN-LII CHENG | European Journal of Cancer | 17 | 17 | |
90 | 2011 | Prognostic molecular markers in Women aged 35 years or younger with breast cancer: Is there a difference from the older patients? | CHING-HUNG LIN ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; KUAN-TING KUO ; Wang C.-C.; You S.-L.; PO-HAN LIN ; DWANG-YING CHANG ; WEN-HUNG KUO ; KING-JEN CHANG ; ANN-LII CHENG | Journal of Clinical Pathology | 8 | 8 | |
91 | 2011 | Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era | I-CHUN CHEN ; CHING-HUNG LIN ; CHIUN-SHENG HUANG ; HUANG-CHUN LIEN ; CHIUN HSU ; WEN-HUNG KUO ; YEN-SHEN LU ; ANN-LII CHENG | Breast Cancer Research and Treatment | 84 | 74 | |
92 | 2011 | Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer | YEN-SHEN LU ; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; SUNG-HSIN KUO ; CHIUN-SHENG HUANG | Cancer Chemotherapy and Pharmacology | 10 | 8 | |
93 | 2010 | Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma | Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; SUNG-HSIN KUO ; CHIH-HUNG HSU ; YEN-SHEN LU ; ANN-LII CHENG | Cancer Letters | 19 | 19 | |
94 | 2010 | Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin | YU-YUN SHAO ; KUAN-TING KUO ; Hu F.-C.; YEN-SHEN LU ; CHIUN-SHENG HUANG ; JAU-YU LIAU ; Lee W.-C.; CHIUN HSU ; WEN-HUNG KUO ; KING-JEN CHANG ; CHING-HUNG LIN ; ANN-LII CHENG | Japanese Journal of Clinical Oncology | 28 | 24 | |
95 | 2010 | Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation | PO-HAN LIN ; YEN-SHEN LU ; CHING-HUNG LIN ; DWANG-YING CHANG ; CHIUN-SHENG HUANG ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 6 | 4 | |
96 | 2010 | O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers | PEI-FANG WU; KUAN-TING KUO ; LU-TING KUO ; YI-TING LIN; WEI-CHUNG LEE; YEN-SHEN LU ; CHIH-HSIN YANG ; RUEY-MEEI WU ; YONG-KWANG TU ; JUI-CHANG TASI ; HAM-MIN TSENG; SHENG-HONG TSENG ; ANN-LII CHENG ; CHING-HUNG LIN | Lung Cancer | 26 | 26 | |
97 | 2010 | Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy | CHING-HUNG LIN ; HUANG-CHUN LIEN ; Hu F.-C.; YEN-SHEN LU ; SUNG-HSIN KUO ; Wu L.-C.; You S.-L.; ANN-LII CHENG ; KING-JEN CHANG ; CHIUN-SHENG HUANG | Journal of Zhejiang University: Science B | 8 | 11 | |
98 | 2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
99 | 2009 | Molecular subtypes of breast cancer emerging in young women in Taiwan: Evidence for more than just westernization as a reason for the disease in Asia | CHING-HUNG LIN ; JAU-YU LIAU ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; Lee W.-C.; KUAN-TING KUO ; Ying-Chun Shen ; SUNG-HSIN KUO ; Lan C.; Liu J.M.; WEN-HUNG KUO ; KING-JEN CHANG ; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 99 | 95 | |
100 | 2009 | Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma | DA-LIANG OU ; Ying-Chun Shen ; JA-DER LIANG ; Liou J.-Y.; SUNG-LIANG YU ; Fan H.-H.; Wang D.-S.; YEN-SHEN LU ; CHIUN HSU ; ANN-LII CHENG | Clinical Cancer Research | 32 | 34 | |
101 | 2008 | NF-κB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells | Gao M.; Yeh P.Y.; YEN-SHEN LU ; Chang W.C.; Kuo M.-L.; ANN-LII CHENG | Biochemical and Biophysical Research Communications | 23 | 19 | |
102 | 2008 | Differential expression of glucocorticoid receptor in carcinomas of the human digestive system | HUANG-CHUN LIEN ; YEN-SHEN LU ; CHIA-TUNG SHUN ; Yao Y.-T.; Chang W.-C.; ANN-LII CHENG | Histopathology | 18 | 17 | |
103 | 2008 | OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma | Gao M.; Yeh P.Y.; YEN-SHEN LU ; CHIH-HUNG HSU ; Chen K.-F.; Lee W.-C.; Feng W.-C.; Chen C.-S.; Kuo M.-L.; ANN-LII CHENG | Cancer Research | 131 | 123 | |
104 | 2008 | FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C δ signaling | Hung J.-H.; YEN-SHEN LU ; Wang Y.-C.; Ma Y.-H.; Wang D.-S.; Kulp S.K.; Muthusamy N.; Byrd J.C.; ANN-LII CHENG ; Chen C.-S. | Cancer Research | 96 | 93 | |
105 | 2008 | The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers | CHIUN-SHENG HUANG ; SUNG-HSIN KUO ; HUANG-CHUN LIEN ; Yang S.-Y.; You S.-L.; Shen C.-Y.; CHING-HUNG LIN ; YEN-SHEN LU ; KING-JEN CHANG | Oncologist | 19 | 18 | |
106 | 2008 | Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients | SUNG-HSIN KUO ; HUANG-CHUN LIEN ; You S.-L.; YEN-SHEN LU ; CHING-HUNG LIN ; Chen T.-Z.; CHIUN-SHENG HUANG | Breast | 13 | 12 | |
107 | 2008 | Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells | Chen K.-F.; Yeh P.-Y.; KUN-HUEI YEH ; YEN-SHEN LU ; SHANG-YI HUANG ; ANN-LII CHENG | Cancer Research | 114 | 105 | |
108 | 2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |
109 | 2007 | Pneumatosis coli after etoposide chemotherapy for breast cancer | I-LUN SHIH ; YEN-SHEN LU ; HSIU-PO WANG ; KAO-LANG LIU | Journal of Clinical Oncology | 12 | 12 | |
110 | 2007 | Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma | YEN-SHEN LU ; Kashida Y.; Kulp S.K.; Wang Y.-C.; Wang D.; Hung J.-H.; Tang M.; ZHONG-ZHE LIN ; Chen T.-J.; ANN-LII CHENG ; Chen C.-S. | Hepatology | 83 | 83 | |
111 | 2006 | Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity | YEN-SHEN LU ; HUANG-CHUN LIEN ; Yeh P.-Y.; SUNG-HSIN KUO ; Chang W.-C.; Kuo M.-L.; ANN-LII CHENG | Lung Cancer | 35 | 34 | |
112 | 2006 | Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms | HUANG-CHUN LIEN ; YEN-SHEN LU ; ANN-LII CHENG ; Chang W.-C.; YUNG-MING JENG ; Kuo Y.-H.; CHIUN-SHENG HUANG ; KING-JEN CHANG ; Yao Y.-T. | Journal of Pathology | 48 | 48 | |
113 | 2006 | Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer | Ch'ang H.-J.; Wang C.-C.; ANN-LII CHENG ; CHIUN HSU ; YEN-SHEN LU ; MING-CHU CHANG ; Lin J.-T.; HSIU-PO WANG ; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 8 | 8 | |
114 | 2006 | Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-κB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa | YEN-SHEN LU ; Yeh P.-Y.; Chuang S.-E.; Gao M.; Kuo M.-L.; ANN-LII CHENG | Journal of Endocrinology | 23 | 21 | |
115 | 2005 | Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors | YEN-SHEN LU ; HUANG-CHUN LIEN ; Yeh P.-Y.; KUN-HUEI YEH ; Kuo M.-L.; SUNG-HSIN KUO ; ANN-LII CHENG | World Journal of Gastroenterology | 26 | 25 | |
116 | 2005 | Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.-F.; CHIUN HSU ; SUNG-HSIN KUO ; Li Jr. S.; ANN-LII CHENG | Oncology | 22 | 22 | |
117 | 2005 | Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.F.; Chao H.J.; Ta-Chen Huang ; Chung C.Y.; Chang C.S.; CHIH-HSIN YANG ; ANN-LII CHENG | British Journal of Cancer | 7 | 7 | |
118 | 2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG ; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU ; YEN-SHEN LU ; HWEI-FANG TIEN ; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; PEI-JER CHEN | World Journal of Gastroenterology | 18 | 14 | |
119 | 2004 | Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | YEN-SHEN LU ; Hsu C; Li C.-C; SUNG-HSIN KUO ; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. | Hepato-Gastroenterology | 14 | 13 | |
120 | 2004 | Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI | YEUN-CHUNG CHANG ; CHIUN-SHENG HUANG ; Liu Y.-J.; Chen J.-H.; YEN-SHEN LU ; WEN-YIH TSENG | Physics in Medicine and Biology | 70 | 63 | |
121 | 2004 | Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract | CHIUN HSU ; Ying-Chun Shen ; CHIH-HSIN YANG ; KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG | British Journal of Cancer | 42 | 40 | |
122 | 2003 | High-dose Tamoxifen Modulates Drug Resistance to Doxorubicin, Dacarbazine and Ifosfamide in Metastatic Uterine Leiomyosarcoma | KUN-HUEI YEH ; YEN-SHEN LU ; Hsiao C.-H.; ANN-LII CHENG | Anticancer Research | 3 | 3 | |
123 | 2002 | Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells | Chuang S.-E.; Yeh P.-Y.; YEN-SHEN LU ; Lai G.-M.; Liao C.-M.; Gao M.; ANN-LII CHENG | Biochemical Pharmacology | 161 | 138 | |
124 | 2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
125 | 2002 | Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma | CHIUN HSU ; CHIUN-SHENG HUANG ; Chao T.-Y.; YEN-SHEN LU ; Bu C.-F.; Chen M.M.; KING-JEN CHANG ; ANN-LII CHENG | Cancer | 12 | 11 | |
126 | 1996 | Transient ‘Milky Urine’ after Cardiac Catheterization: Another Unreported Cause of Non-Parasitic Chyluria | Chen H.-S.; Yen T.-S.; YEN-SHEN LU ; JYH-CHIN YANG ; Ko Y.-L. | Nephron | 9 | 8 |